

Feldmann, Heinrich (NIH/NIAID) [E]

From: Mahoney, Frank (CDC/CGH/GID)
Sent: Monday, October 20, 2014 11:45 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Pineda, Mark (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: MOU

I talked with the minister about signing a separate agreement of NIH and Dod. he is agreeable to do this....

frank

(NIH)

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

----- Original Message -----

From: Nichol, Stuart T. (CDC/DID/NCEZID)

Sent: Sunday, October 19, 2014 10:59 AM Eastern Standard Time

To: Feldmann, Heinrich (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Casellas, Rafael (NIH/NIAMS) [E]

Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID)

Subject: Fw: MOU

Can you coordinate on NIH side as to who will be developing NIH MOU with Liberian MOH ? Frank Mahoney in Liberia is willing to try to assist with getting an NIH-MOH MOU in place. Who would sign from the NIH side?

Stuart

Sent from my BlackBerry 10 smartphone.

(NIH)

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

On 10/19/14, 10:59 AM, "Nichol, Stuart T. (CDC/OID/NCEZID)" <stn1@CDC.GOV> wrote:

- >Can you coordinate on NIH side as to who will be developing NIH MOU
- >with Liberian MOH ? Frank Mahoney in Liberia is willing to try to
- >assist with getting an NIH-MOH MOU in place. Who would sign from the NIH side?
- >
- >Stuart
- >
- >Sent from my BlackBerry 10 smartphone.

(NIH)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Fields, Barry (CDC/CGH/DGHP)
Sent: Thursday, October 16, 2014 1:22 PM
To: Nichol, Stuart T. (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Self, Joshua S. (CDC/OID/NCEZID); Rayfield, Mark (CDC/CGH/DGHP)
Cc: De wit, Emmie (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Rayfield, Mark (CDC/CGH/DGHP)
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Point taken. Mark and I have been talking. There are several transition details and we are discussing but need to include NIH. I want some EOC time credit. :)

Sent from my BlackBerry 10 smartphone.

From: Nichol, Stuart T. (CDC/OID/NCEZID)
Sent: Thursday, October 16, 2014 10:18 PM
To: Fields, Barry (CDC/CGH/DGHP); Feldmann, Heinrich (NIH/NIAID) [E]; Self, Joshua S. (CDC/OID/NCEZID); Rayfield, Mark (CDC/CGH/DGHP)
Cc: De wit, Emmie (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]; Rayfield, Mark (CDC/CGH/DGHP)
Subject: RE: Ebola Outbreak Response Monrovia Liberia

Barry - I thought you and Mark were the ones doing the coordination ☺ We can delay these guys.

From: Fields, Barry (CDC/CGH/DGHP)
Sent: Thursday, October 16, 2014 3:12 PM
To: Nichol, Stuart T. (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Self, Joshua S. (CDC/OID/NCEZID); Rayfield, Mark (CDC/CGH/DGHP)
Cc: De wit, Emmie (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola Outbreak Response Monrovia Liberia

We are sending two CDC lab staff according to Mark Rayfield. I agree with Heinz that we. Don't need. 7 people in that lab, the NIH and CDC lab deployments. Should be coordinated.

Sent from my BlackBerry 10 smartphone.

From: Nichol, Stuart T. (CDC/OID/NCEZID)
Sent: Thursday, October 16, 2014 10:06 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Self, Joshua S. (CDC/OID/NCEZID); Fields, Barry (CDC/CGH/DGHP)
Cc: De wit, Emmie (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: Ebola Outbreak Response Monrovia Liberia

I wasn't aware we were sending two folks from Atlanta (I'm out of the loop on the deployment schedule). I will check and get back to you.

Stuart

(NIH)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Fields, Barry (CDC/CGH/DGHP)
Sent: Thursday, October 16, 2014 1:12 PM
To: Nichol, Stuart T. (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Self, Joshua S. (CDC/OID/NCEZID); Rayfield, Mark (CDC/CGH/DGHP)
Cc: De wit, Emmie (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola Outbreak Response Monrovia Liberia

We are sending two CDC lab staff according to Mark Rayfield. I agree with Heinz that we. Don't need 7 people in that lab, the NIH and CDC lab deployments. Should be coordinated.

Sent from my BlackBerry 10 smartphone.

From: Nichol, Stuart T. (CDC/OID/NCEZID)
Sent: Thursday, October 16, 2014 10:06 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Self, Joshua S. (CDC/OID/NCEZID); Fields, Barry (CDC/CGH/DGHP)
Cc: De wit, Emmie (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: Ebola Outbreak Response Monrovia Liberia

I wasn't aware we were sending two folks from Atlanta (I'm out of the loop on the deployment schedule). I will check and get back to you.

Stuart

(NIH)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Fields, Barry (CDC/CGH/DGHP)
Sent: Thursday, October 16, 2014 1:09 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Sent from my BlackBerry 10 smartphone.

(NIH)

From: Self, Joshua S. (CDC/OID/NCEZID)
Sent: Thursday, October 16, 2014 09:02 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola Outbreak Response Monrovia Liberia

Thank you very much for the info Heinz. Hope all is going well with you. Look forward to working with you soon. Best,
Josh

(NIH)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Brooks, John T. (CDC/OID/NCHHSTP)
Sent: Wednesday, October 15, 2014 4:44 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Damon, Inger K. (CDC/OID/NCEZID); Redd, Stephen (CDC/OID/OD)
Cc: George Risi
Subject: RE: Montana

Hi all (including George Risi),

I spoke this afternoon with George Risi at St. Patrick's Hospital in Missoula Montana.

They are presently meeting to discuss capacity to accept patients at their facility. There facilities under contract with NIH to care for persons at the Rocky Mountain laboratories. A principal issue for them is staffing; the nursing staff is small and there is one infectious disease doctor: Dr. Risi!

I offered that if staffing is the issue limiting their ability to offer capacity for Ebola virus patients, then perhaps we could consider offering some assistance in that area. The promises made but the conversation opened.

John

John T. Brooks, M.D.
Medical Care Task Force Lead
CDC Emergency Ebola Response

(b)(6)

(NIH)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Damon, Inger K. (CDC/OID/NCEZID)
Sent: Wednesday, October 15, 2014 11:14 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Brooks, John T. (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD); George Risi
Subject: Re: Montana

Thanks, Heinz
Will reach out after the meeting I am in ends

Inger

Inger Damon
Director Division of High Consequence Pathogens and Pathology NCEZID CDC

(NIH)

> ----- Original Message -----
> From: Damon, Inger K. (CDC/OID/NCEZID)
> Sent: Wednesday, October 15, 2014 12:41 PM Eastern Standard Time
> To: Brooks, John T. (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD);
> Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: Montana
>
> Who would be the Poc for the Montana facility to ask if ready for
> Ebola patients? Adding Heinz
>
> Inger
>
> Inger Damon
> Director Division of High Consequence Pathogens and Pathology NCEZID
> CDC
>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Damon, Inger K. (CDC/OID/NCEZID)
Sent: Wednesday, October 15, 2014 10:50 AM
To: Redd, Stephen (CDC/OID/OD)
Cc: Brooks, John T. (CDC/OID/NCHHSTP); Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Montana

Need ASAP

Inger

Inger Damon
Director Division of High Consequence Pathogens and Pathology NCEZID CDC

> On Oct 15, 2014, at 12:46 PM, Redd, Stephen (CDC/OID/OD) <scr1@cdc.gov> wrote:
>
> Will check with Will Walters.
>
> Original Message
> From: Damon, Inger K. (CDC/OID/NCEZID)
> Sent: Wednesday, October 15, 2014 12:41 PM
> To: Brooks, John T. (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD);
> Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: Montana
>
>
> Who would be the Poc for the Montana facility to ask if ready for
> Ebola patients? Adding Heinz
>
> Inger
>
> Inger Damon
> Director Division of High Consequence Pathogens and Pathology NCEZID
> CDC
>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Damon, Inger K. (CDC/OID/NCEZID)
Sent: Wednesday, October 15, 2014 10:42 AM
To: Brooks, John T. (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD); Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Montana

Who would be the Poc for the Montana facility to ask if ready for Ebola patients? Adding Heinz

Inger

Inger Damon
Director Division of High Consequence Pathogens and Pathology NCEZID CDC

Feldmann, Heinrich (NIH/NIAID) [E]

From: Walke, Henry (CDC/OID/NCEZID)
Sent: Saturday, October 11, 2014 3:24 AM
To: Flannery, Brendan (CDC/OID/NCIRD); 'MSFOCB-Monrovia-LiaisonOfficer@brussels.msf.org'; Thorne, Gregory Immel (CDC/CGH/DGHA); Flaherty, Patrick (CDC/OID/NCHHSTP); Mott, Joshua (CDC/OID/NCIRD)
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: request for Chinese delegation visit to ELWA 3 lab

Heinz is this possible?
Henry Walke from cdc, I took over from Brendan

From: Flannery, Brendan (CDC/OID/NCIRD)
Sent: Saturday, October 11, 2014 09:09 AM
To: 'MSFOCB-Monrovia-LiaisonOfficer@brussels.msf.org' <MSFOCB-Monrovia-LiaisonOfficer@brussels.msf.org>; Walke, Henry (CDC/OID/NCEZID); Thorne, Gregory Immel (CDC/CGH/DGHA); Flaherty, Patrick (CDC/OID/NCHHSTP); Mott, Joshua (CDC/OID/NCIRD)
Subject: Re: request for Chinese delegation visit to ELWA 3 lab

Yes--great idea. I left yesterday Copying henry walke to organize. He has my phone number
Thanks for all the help
Brendan

From: MSFOCB-Monrovia-LiaisonOfficer [mailto:MSFOCB-Monrovia-LiaisonOfficer@brussels.msf.org]
Sent: Saturday, October 11, 2014 03:34 AM Eastern Standard Time
To: Flannery, Brendan (CDC/OID/NCIRD)
Subject: request for Chinese delegation visit to ELWA 3 lab

Hi Brendan,
The Chinese have an Advanced Team of officials who are doing a fact-finding visit for possible deployment of a medical team for Ebola in Liberia. In addition to visiting ELWA, they requested to visit the CDC lab. They should be at ELWA at about 9 am tomorrow.
Would a visit to the lab be possible?
Thanks!
Kris

Kris Torgeson
Liaison Officer, MSF
Monrovia, Liberia
+231 (0) 77 50 65 878

Feldmann, Heinrich (NIH/NIAID) [E]

From: Saindon, John M. (CDC/OPHSS/OD)
Sent: Friday, October 10, 2014 11:39 AM
To: Flynn, Jesse M CTR OSD OUSD ATL (US); Towner, Jonathan (Jon) (CDC/OID/NCEZID); Bird, Brian (CDC/OID/NCEZID); Rayfield, Mark (CDC/CGH/DGHP); Bartee, Maureen S CIV (US); Watson, Ian D CIV (US); Newman, Carl I CIV (US); Nichol, Stuart T. (CDC/OID/NCEZID); Norwood, David A, Jr CIV USARMY MEDCOM USAMRIID (US); Smith, Michael A CIV (US); Stroehrer, Ute (CDC/OID/NCEZID); Geibe, Jesse R. (CDC/OPHPR/OD); Montgomery, Joel M. (CDC/CGH/DGHP); Fields, Barry (CDC/CGH/DGHP); Feldman, Heinrich (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Smith, Jennifer B CIV (US); guillermo.pimentel@med.navy.mil
Cc: Hensley, Lisa (NIH/NIAID) [E]; Woollen, Neal E LTC USARMY MEDCOM USAMRIID (US); Dorau, Andrew C CIV DTRA J3-7 (US)
Subject: RE: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call

Hello Everyone!

With Monday being a federal holiday, are we in concurrence that we should cancel this meeting Monday October 13th?

Please advise if we still need have this meeting on Monday.

R.

John M. Saindon, DrHSc, MT
Ebola Laboratory Response Team
Emergency Operations Center Room #3028A
Centers for Disease Control and Prevention (CDC)
Phone: 404-498-2242 BB: 404-580-4658



FOR OFFICIAL USE ONLY

Sensitive But Unclassified (SBU) This document may contain sensitive information that may be exempt from public release under the Freedom of Information Act (FOIA) (5 U.S.C. 552). This information is for internal government use only. Further distribution to authorized personnel with a "need to know" and for situation awareness is authorized by the Centers for Disease Control and Prevention.

-----Original Appointment-----

From: Flynn, Jesse M CTR OSD OUSD ATL (US) [mailto:jesse.m.flynn.ctr@mail.mil]
Sent: Friday, September 05, 2014 5:59 PM
To: Flynn, Jesse M CTR OSD OUSD ATL (US); Towner, Jonathan (Jon) (CDC/OID/NCEZID); Bird, Brian

(NIH)

On 9/12/14 7:02 AM, "Fields, Barry (CDC/CGH/DGHP)" <bsf2@CDC.GOV> wrote:

>Here are the sequences if you need them.

>

>Barry

>

>

>

>Ebola Zaïre F

>

>TGG GCT GAA AAY TGC TAC AAT C

>

>Ebola Zaire R

>

>CTT TGC GMA CAT ASC GGC AC

>

>Ebola Zaire Probe

>

>5 - CT AGC AGC GCC AGA CGG- 3'

Feldmann, Heinrich (NIH/NIAD) [E]

From: Róta, Paul (CDC/OID/NCIRD)
Sent: Wednesday, October 08, 2014 8:57 AM
To: Martha Mulks
Cc: Feldmann, Heinrich (NIH/NIAD) [E]
Subject: RE: Contact for virologist working with Ebola?

Hi Martha,

Nice to hear from you. I will forward your e-mail to the Ebola virology team. You might also consider contacting Dr. Heinz Feldman (feldmannh@niaid.nih.gov) who works with Ebola at the NIH Rocky MTN Labs.

I am here at CDC still working on measles and mumps. How are things at MSU? My nephew is now a freshman at MSU, so I may have to come up for a visit one of these days.

Best regards,

Paul

From: Martha Mulks [<mailto:mulks@msu.edu>]
Sent: Wednesday, October 08, 2014 10:22 AM
To: Róta, Paul (CDC/OID/NCIRD)
Subject: Contact for virologist working with Ebola?

Dear Paul,

Serious voice from the past!

My lab is working with a company in Michigan, UrthTech, that makes a range of disinfectants and sanitizers for use in hospitals, on produce, on carcasses, and in homes. My contact, Dr. Aziz Awad, tells me that one of his sanitizers has been shown to work very well on unenveloped viruses, such as norovirus, and that his sanitizer works in the presence of organic material and is more stable than 10% bleach. He wonders whether it would be useful in the Ebola epidemic, and would like to find someone willing to test its efficacy against Ebola virus. I told him that I would contact the two virologists that I know at CDC, you and Ian York, and ask whether you think his sanitizer would be of interest to CDC and who he might contact for some guidance. I will say that we have found his various products to be extremely effective, with one formulation killing *E. coli*, *Pseudomonas aeruginosa*, *Staph. aureus*, and *Enterococcus faecalis* in less than 1 minute (sometimes less than 15 seconds), and another killing anthrax spores in 30-60 minutes.

Hope all is well with you.

Regards,
Martha Mulks

Martha H. Mulks, Ph.D.
Director, Center for Microbial Pathogenesis
Professor, Dept. of Microbiology & Molecular Genetics
5193 Biomedical & Physical Sciences Building
567 Wilson Road
Michigan State University
East Lansing, MI 48824

Phone: 517-884-5365
Email: mulks@msu.edu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Khan, Ali S <ali.khan@unmc.edu>
Sent: Wednesday, October 08, 2014 6:37 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: CMX-001 or T705

Yea. We will coordinate with WHO since we will need all the help we can get.
But let's lock down a treatment facility.

All

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

(NIH)

>

> ----- Original Message -----

> **From:** Khan, Ali S [mailto:ali.khan@unmc.edu]

> **Sent:** Tuesday, October 07, 2014 11:46 PM Eastern Standard Time

> **To:** Uyeki, Timothy M. (CDC/OID/NCIRD)

> **Cc:** Feldmann, Heinrich (NIH/NIAID) [E]; De Alba, Armando <armando.dealba@unmc.edu>

> **Subject:** Re: CMX-001 or T705

>

> Thanks Tim for these ideas. Very helpful. With 50% case fatality, the power calculations are simple. We can do this.

> Chatted with Lu today.

> Waiting for Heinz to check with MSF.

> Best and thank you for the great info going out and the individual clinician consultation.

>

> Ali

>

> * UNMC College of Public Health

> Bringing innovative solutions to

> healthier communities in Nebraska

> and worldwide

>

>> On Oct 7, 2014, at 10:26 PM, Uyeki, Timothy M. (CDC/OID/NCIRD) <tmu0@cdc.gov> wrote:

>>

>> in the West Africa setting, unless the Ebola Treatment Unit is providing IV fluid hydration, would need to use oral therapies. There clearly are some therapies that would need to be administered intravenously. But an oral medication is what is needed - assuming the patient is not in the profuse diarrheal phase or vomiting phase - issues with drug absorption. The comparison group is key - ideally, an RCT would be best, but you do not need a placebo - can randomize to standard of care, but need to standardize the clinical care in the study population. Virological monitoring to compare

Feldmann, Heinrich (NIH/NIAID) [E]

From: Khan, Ali S <ali.khan@unmc.edu>
Sent: Tuesday, October 07, 2014 9:46 PM
To: Uyeki, Timothy M. (CDC/OID/NCIRD)
Cc: Feldmann, Heinrich (NIH/NIAID) [E], De Alba, Armando
Subject: Re: CMX-001 or T705

Thanks Tim for these ideas. Very helpful. With 50% case fatality, the power calculations are simple. We can do this.
Chatted with Lu today.
Waiting for Heinz to check with MSF.
Best and thank you for the great info going out and the individual clinician consultation.

Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

> On Oct 7, 2014, at 10:26 PM, Uyeki, Timothy M. (CDC/OID/NCIRD) <tmu0@cdc.gov> wrote:

>

> In the West Africa setting, unless the Ebola Treatment Unit is providing IV fluid hydration, would need to use oral therapies. There clearly are some therapies that would need to be administered intravenously. But an oral medication is what is needed - assuming the patient is not in the profuse diarrheal phase or vomiting phase - issues with drug absorption. The comparison group is key - ideally, an RCT would be best, but you do not need a placebo - can randomize to standard of care, but need to standardize the clinical care in the study population. Virological monitoring to compare pre-treatment viral load and change in viral load as a secondary outcome with the primary outcome being survival would be highly desirable. Just some quick thoughts.

> Tim

> -----Original Message-----

> From: Khan, Ali S [mailto:ali.khan@unmc.edu]

> Sent: Monday, October 06, 2014 11:40 PM

> To: Uyeki, Timothy M. (CDC/OID/NCIRD)

> Cc: Feldmann, Heinrich (NIH/NIAID) [E]

> Subject: Re: CMX-001 or T705

>

> Thanks Tim

> I think we may try to launch a trial. Hopefully Heinz can find a clinical site. And provide lab backup.

>

> Please share thoughts

>

> Ali

>

> * UNMC College of Public Health

> Bringing innovative solutions to

> healthier communities in Nebraska

> and worldwide

>

>> On Oct 6, 2014, at 10:34 PM, Uyeki, Timothy M. (CDC/OID/NCIRD) <tmu0@cdc.gov> wrote:

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

----- Original Message -----

From: Nichol, Stuart T. (CDC/OID/NCEZID)

Sent: Sunday, October 19, 2014 10:59 AM Eastern Standard Time

To: Feldmann, Heinrich (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Casellas, Rafael (NIH/NIAMS) [E]

Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID)

Subject: Fw: MOU

Can you coordinate on NIH side as to who will be developing NIH MOU with Liberian MOH ? Frank Mahoney in Liberia is willing to try to assist with getting an NIH-MOH MOU in place. Who would sign from the NIH side?

Stuart

Sent from my BlackBerry 10 smartphone.

(NIH)

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

From: Self, Joshua S. (CDC/OID/NCEZID)

Sent: Thursday, October 16, 2014 03:33 PM Eastern Standard Time

To: Feldmann, Heinrich (NIH/NIAID) [E]

Cc: De Wit, Emmie (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Nichol, Stuart T. (CDC/OID/NCEZID); Fields, Barry (CDC/CGH/DGHP); Rayfield, Mark (CDC/CGH/DGHP); Zemtsova, Galina E. (CDC/OID/NCEZID)

Subject: RE: Ebola Outbreak Response Monrovia Liberia

Heinz,

We will be delaying a week. This will give me more time to round up some supplies (we are getting 2 large cases to bring supplies) and some other things.

Best,

Josh

(NIH)

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

From: Fields, Barry (CDC/CGH/DGHP)
Sent: Thursday, October 16, 2014 03:21 PM Eastern Standard Time
To: Nichol, Stuart T. (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Self, Joshua S. (CDC/OID/NCEZID); Rayfield, Mark (CDC/CGH/DGHP)
Cc: De Wit, Emmie (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Rayfield, Mark (CDC/CGH/DGHP)
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Point taken. Mark and I have been talking. There are several transition details and we are discussing but need to include NIH. I want some EOC time credit. :)

Sent from my BlackBerry 10 smartphone.

From: Nichol, Stuart T. (CDC/OID/NCEZID)
Sent: Thursday, October 16, 2014 10:18 PM
To: Fields, Barry (CDC/CGH/DGHP); Feldmann, Heinrich (NIH/NIAID) [E]; Self, Joshua S. (CDC/OID/NCEZID); Rayfield, Mark (CDC/CGH/DGHP)
Cc: De Wit, Emmie (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]; Rayfield, Mark (CDC/CGH/DGHP)
Subject: RE: Ebola Outbreak Response Monrovia Liberia

Barry - I thought you and Mark were the ones doing the coordination ☺ We can delay these guys.

From: Fields, Barry (CDC/CGH/DGHP)
Sent: Thursday, October 16, 2014 3:12 PM
To: Nichol, Stuart T. (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Self, Joshua S. (CDC/OID/NCEZID); Rayfield, Mark (CDC/CGH/DGHP)
Cc: De Wit, Emmie (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola Outbreak Response Monrovia Liberia

We are sending two CDC lab staff according to Mark Rayfield. I agree with Heinz that we. Don't need. 7 people in that lab, the NIH and CDC lab deployments. Should be coordinated.

Sent from my BlackBerry 10 smartphone.

From: Nichol, Stuart T. (CDC/OID/NCEZID)
Sent: Thursday, October 16, 2014 10:06 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Self, Joshua S. (CDC/OID/NCEZID); Fields, Barry (CDC/CGH/DGHP)
Cc: De Wit, Emmie (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: Ebola Outbreak Response Monrovia Liberia

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

From: Self, Joshua S. (CDC/OID/NCEZID)
Sent: Thursday, October 16, 2014 09:02 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola Outbreak Response Monrovia Liberia

Thank you very much for the info Heinz. Hope all is going well with you. Look forward to working with you soon. Best,
Josh

(NIH)

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

From: Self, Joshua S. (CDC/OID/NCEZID)
Sent: Thursday, October 16, 2014 11:48 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola Outbreak Response Monrovia Liberia

If there is anything that you can think of that you would like for me to bring, I will try my best to do so. Best, Josh

(NIH)

From: Self, Joshua S. (CDC/OID/NCEZID)
Sent: Thursday, October 16, 2014 09:02 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola Outbreak Response Monrovia Liberia

Thank you very much for the info Heinz. Hope all is going well with you. Look forward to working with you soon. Best,
Josh

(NIH)

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

From: Self, Joshua S. (CDC/OID/NCEZID)
Sent: Thursday, October 16, 2014 09:02 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola Outbreak Response Monrovia Liberia

Thank you very much for the info Heinz. Hope all is going well with you. Look forward to working with you soon. Best,
Josh

(NIH)

From: Self, Joshua S. (CDC/OID/NCEZID)
Sent: Wednesday, October 15, 2014 11:58 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

From: Self, Joshua S. (CDC/OID/NCEZID)
Sent: Wednesday, October 15, 2014 11:58 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola Outbreak Response Monrovia Liberia

Dr. Feldmann,

I am scheduled to leave for Liberia on 10/19/2014 as part of the laboratory component. Is it possible to get a list of the PPE that will be used and protocols for the processes (inactivation, RNA extraction, PCR, etc.) that we will be doing? I have a lot of laboratory experience, and would like to become familiar with specific techniques concerning Ebola laboratory techniques in less than optimal conditions. Thank you for your time and consideration. I look forward to working with you in the near future.

Safe travels to Liberia.

Best regards,

Joshua Self
Microbiologist

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

----- Original Message -----

From: Damon, Inger K. (CDC/OID/NCEZID)

Sent: Wednesday, October 15, 2014 12:41 PM Eastern Standard Time

To: Brooks, John T. (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD); Feldmann, Heinrich (NIH/NIAID) [E]

Subject: Montana

Who would be the Poc for the Montana facility to ask if ready for Ebola patients? Adding Heinz

Inger

Inger Damon

Director Division of High Consequence Pathogens and Pathology NCEZID CDC

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

----- Original Message -----

From: Damon, Inger K. (CDC/OID/NCEZID)

Sent: Wednesday, October 15, 2014 12:41 PM Eastern Standard Time

To: Brooks, John T. (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD); Feldmann, Heinrich (NIH/NIAID) [E]

Subject: Montana

Who would be the Poc for the Montana facility to ask if ready for Ebola patients? Adding Heinz

Inger

Inger Damon

Director Division of High Consequence Pathogens and Pathology NCEZID.CDC

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

From: Walke, Henry (CDC/OID/NCEZID)
Sent: Saturday, October 11, 2014 05:23 AM Eastern Standard Time
To: Flannery, Brendan (CDC/OID/NCIRD); 'MSFOCB-Monrovia-LiaisonOfficer@brussels.msf.org' <MSFOCB-Monrovia-LiaisonOfficer@brussels.msf.org>; Thorne, Gregory Immel (CDC/CGH/DGHA); Flaherty, Patrick (CDC/OID/NCHHSTP); Mott, Joshua (CDC/OID/NCIRD)
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: request for Chinese delegation visit to ELWA 3 lab

Heinz is this possible?

Henry Walke from cdc, I took over from Brendan

From: Flannery, Brendan (CDC/OID/NCIRD)
Sent: Saturday, October 11, 2014 09:09 AM
To: 'MSFOCB-Monrovia-LiaisonOfficer@brussels.msf.org' <MSFOCB-Monrovia-LiaisonOfficer@brussels.msf.org>; Walke, Henry (CDC/OID/NCEZID); Thorne, Gregory Immel (CDC/CGH/DGHA); Flaherty, Patrick (CDC/OID/NCHHSTP); Mott, Joshua (CDC/OID/NCIRD)
Subject: Re: request for Chinese delegation visit to ELWA 3 lab

Yes--great idea. I left yesterday. Copying henry walke to organize. He has my phone number

Thanks for all the help

Brendan

From: MSFOCB-Monrovia-LiaisonOfficer [mailto:MSFOCB-Monrovia-LiaisonOfficer@brussels.msf.org]
Sent: Saturday, October 11, 2014 03:34 AM Eastern Standard Time
To: Flannery, Brendan (CDC/OID/NCIRD)
Subject: request for Chinese delegation visit to ELWA 3 lab

Hi Brendan,

The Chinese have an Advanced Team of officials who are doing a fact-finding visit for possible deployment of a medical team for Ebola in Liberia. In addition to visiting ELWA, they requested to visit the CDC lab. They should be at ELWA at about 9 am tomorrow.

Would a visit to the lab be possible?

Thanks!

Kris

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

On 9/12/14 7:02 AM, "Fields, Barry (CDC/CGH/DGHP)" <bsf2@CDC.GOV> wrote:

>Here are the sequences if you need them.

>

>Barry

>

>

>

>Ebola Zaire F

>

>TGG GCT GAA AAY TGC TAC AAT C

>

>Ebola Zaire R

>

>CTT TGC GMA CAT ASC GGC AC

>

>Ebola Zaire Probe

>

>5'- CT AGC AGC GCC AGA CGG- 3'

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

----- Original Message -----

From: Khan, Ali S [mailto:ali.khan@unmc.edu]

Sent: Tuesday, October 07, 2014 11:46 PM Eastern Standard Time

To: Uyeki, Timothy M. (CDC/OID/NCIRD)

Cc: Feldmann, Heinrich (NIH/NIAID) [E]; De Alba, Armando <armando.dealba@unmc.edu>

Subject: Re: CMX-001 or T705

Thanks Tim for these ideas. Very helpful. With 50% case fatality, the power calculations are simple. We can do this. Chatted with Lu today.

Waiting for Heinz to check with MSF.

Best and thank you for the great info going out and the individual clinician consultation.

Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

> On Oct 7, 2014, at 10:26 PM, Uyeki, Timothy M. (CDC/OID/NCIRD) <tmu0@cdc.gov> wrote:

>

> in the West Africa setting, unless the Ebola Treatment Unit is providing IV fluid hydration, would need to use oral therapies. There clearly are some therapies that would need to be administered intravenously. But an oral medication is what is needed - assuming the patient is not in the profuse diarrheal phase or vomiting phase - issues with drug absorption. The comparison group is key - ideally, an RCT would be best, but you do not need a placebo - can randomize to standard of care, but need to standardize the clinical care in the study population. Virological monitoring to compare pre-treatment viral load and change in viral load as a secondary outcome with the primary outcome being survival would be highly desirable. Just some quick thoughts.

> Tim

> -----Original Message-----

> From: Khan, Ali S [mailto:ali.khan@unmc.edu]

> Sent: Monday, October 06, 2014 11:40 PM

> To: Uyeki, Timothy M. (CDC/OID/NCIRD)

> Cc: Feldmann, Heinrich (NIH/NIAID) [E]

> Subject: Re: CMX-001 or T705

>

> Thanks Tim

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

----- Original Message -----

From: Khan, Ali S [mailto:ali.khan@unmc.edu]

Sent: Tuesday, October 07, 2014 11:46 PM Eastern Standard Time

To: Uyeki, Timothy M. (CDC/OID/NCIRD)

Cc: Feldmann, Heinrich (NIH/NIAID) [E]; De Alba, Armando <armando.dealba@unmc.edu>

Subject: Re: CMX-001 or T705

Thanks Tim for these ideas. Very helpful. With 50% case fatality, the power calculations are simple. We can do this. Chatted with Lu today.

Waiting for Heinz to check with MSF.

Best and thank you for the great info going out and the individual clinician consultation.

Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

> On Oct 7, 2014, at 10:26 PM, Uyeki, Timothy M. (CDC/OID/NCIRD) <tmu0@cdc.gov> wrote:

>

> In the West Africa setting, unless the Ebola Treatment Unit is providing IV fluid hydration, would need to use oral therapies. There clearly are some therapies that would need to be administered intravenously. But an oral medication is what is needed - assuming the patient is not in the profuse diarrheal phase or vomiting phase - issues with drug absorption. *The comparison group is key - ideally, an RCT would be best, but you do not need a placebo - can randomize to standard of care, but need to standardize the clinical care in the study population.* Virological monitoring to compare pre-treatment viral load and change in viral load as a secondary outcome with the primary outcome being survival would be highly desirable. Just some quick thoughts.

> Tim

> -----Original Message-----

> From: Khan, Ali S [mailto:ali.khan@unmc.edu]

> Sent: Monday, October 06, 2014 11:40 PM

> To: Uyeki, Timothy M. (CDC/OID/NCIRD)

> Cc: Feldmann, Heinrich (NIH/NIAID) [E]

> Subject: Re: CMX-001 or T705

>

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

-----Original Message-----

From: Fields, Barry (CDC/CGH/DGHP)

Sent: Saturday, October 04, 2014 10:33 AM

To: Feldmann, Heinrich (NIH/NIAID) [E]; McNally, Kristin (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]

Cc: Nichol, Stuart T. (CDC/OID/NCEZID); Rollin, Pierre (CDC/OID/NCEZID); Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]

Subject: Re: Expat sample

Good. That vehicle should be parked and not used for transportation for now.

Sent from my BlackBerry 10 smartphone.

(NIH)

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

-----Original Message-----

From: Fields, Barry (CDC/CGH/DGHP)

Sent: Saturday, October 04, 2014 10:23 AM

To: Feldmann, Heinrich (NIH/NIAID) [E]; McNally, Kristin (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Rollin, Pierre (CDC/OID/NCEZID)

Cc: Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]

Subject: Re: Expat sample

Sorry I am a bit disconnected but you should use another driver and vehicle until this is resolved,

Barry

Sent from my BlackBerry 10 smartphone.

(NIH)

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

On Oct 1, 2014, at 9:22, "Juma, Bonventure (CDC/CGH/DGHP)" <xwl2@cdc.gov> wrote:

Let her come to the lab at ELWA 3. The lab is about 100 meters from MSF.

Thanks.

Bonventure Juma.

Sent from my BlackBerry 10 smartphone.

From: Telfer, Jana L. (CDC/ONDIEH/NCEH)

Sent: Wednesday, October 1, 2014 11:58 AM

To: Msfocb-monrovia-emed@brussels.msf.org

Cc: Murphree, Rendi (CDC/OPHPR/DSLRL); Juma, Bonventure (CDC/CGH/DGHP); Panasuk, Brian J. (CDC/OPHPR/DEO)

Subject: NBC News Interest in ELWA Laboratory

Greetings,

NBC News' Dr. Nancy Snyderman has expressed interest in visiting the ELWA laboratory to understand some of the issues and progress made in testing. Might you be able to assist with regard

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

-----Original Message-----

From: Towner, Jonathan (Jon) (CDC/OID/NCEZID)

Sent: Tuesday, September 30, 2014 5:06 PM

To: Feldmann, Heinrich (NIH/NIAID) [E]

Cc: Munster, Vincent (NIH/NIAID) [E]

Subject: Re: Shipment to CDC/NIH Lab - Monrovia - Sept. 15, 2014

Awesome, thanks Heinz. I'll share with them. These guys have a pretty incredible setup built into two trucks that are stitched together. Inside they have a BSC and glove box, but also wear full tyvek, PAPR and N95 underneath...very cautious! I think they wanted to remove the inactivation step since its so rate limiting, but their biosafety officer insisted on it since they have no safety test data. Your outline below will be a big help.

As you can imagine CDC has its hands full with this Texas case.

Cheers,

Jon

(NIH)

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

-----Original Message-----

From: Towner, Jonathan (Jon) (CDC/OID/NCEZID)

Sent: Tuesday, September 30, 2014 4:49 PM

To: Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]

Subject: Re: Shipment to CDC/NIH Lab - Monrovia - Sept. 15, 2014

Vincent or Heinz,

Could one of you sent your extraction SOP you're using in the field for working with Qiagen columns that includes the alcohol step to ensure 100 percent inactivation? I'm here in Sierra Leone and we visited the Chinese lab here outside of Freetown. For RNA extractions they are using Qiagen columns and AVL buffer and an alcohol step, but didn't provide the specifics. I'd like to provide them with the exact same steps you take since I know you've safety tested the process.

I'm trying to convince them to remove a 1 hour 60 deg heat inactivation step prior to using the Qiagen kit, but don't have a specific protocol with me to tell them to use that I know is safe. They're probably doing the exact same as you, but I'd like to be sure. Would that be okay?

Many thanks,

Jon

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

On Sep 29, 2014, at 13:46, "Nichol, Stuart T. (CDC/OID/NCEZID)" <stn1@CDC.GOV> wrote:

That's good news. Dr. Frieden was asking me last night about the progress on this.

Thanks
Stuart

From: Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US)

[<mailto:david.a.norwood.civ@mail.mil>]

Sent: Monday, September 29, 2014 9:45 AM

To: Flynn, Jesse M CTR OSD OUSD ATL (US); Bartee, Maureen S CIV (US); Watson, Ian D CIV (US); Newman, Carl I CIV (US); Nichol, Stuart T. (CDC/OID/NCEZID); Smith, Michael A CIV (US); Stroeher, Ute (CDC/OID/NCEZID); Geibe, Jesse R. (CDC/OPHPR/OD); Montgomery, Joel M. (CDC/CGH/DGHP); Fields, Barry (CDC/CGH/DGHP); Feldmann, Heinrich (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Smith, Jennifer B CIV (US); Pimentel, Guillermo CDR USN NAVMEDRSCHCEN (US)

Cc: Hensley, Lisa (NIH/NIAID) [E]; Woollen, Neal E LTC USARMY MEDCOM USAMRIID (US); Dorau, Andrew C CIV DTRA J3-7 (US)

Subject: RE: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

Classification: UNCLASSIFIED

Caveats: NONE

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

From: Fuller, Serena (CDC/CGH/DGHP)
Sent: Wednesday, September 24, 2014 2:58 PM
To: LORENZIN, Egle
Cc: Neatherlin, John C. (CDC/CGH/DGHP); Fields, Barry (CDC/CGH/DGHP); Feldmann, Heinrich (NIH/NIAID) [E]; Montgomery, Joel M. (CDC/CGH/DGHP); Osanya, Cynthia A. (CDC/CGH/DGHP); UMALI DALANGIN, Khristeen; GURRY, Celine; goarn; GDD-OUTBREAK (CDC); CDC IMS Deployment Coordinator (CDC)
Subject: RE: GOARN Pre-deployment package for Drs Bonventure Juma & Melvin Ochieng (CDC Lab experts), Ebola outbreak, Liberia

Hi Egle,

We would like to deploy the following people to Liberia. Can you send them the pre-deployment package? CDC will arrange travel.

| Name | E-mail | Dates | Role |
|----------------|--|--------------------|------|
| Victor Omballa | vomballa@kemricdc.org | 9/29/14 – 10/27/14 | Lab |
| Collins Owuor | cowuor@kemricdc.org | 9/29/14 – 10/27/14 | Lab |

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

-----Original Message-----

From: Nichol, Stuart T. (CDC/OID/NCEZID)

Sent: Tuesday, September 23, 2014 8:47 AM

To: Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US); 'feldmannh@niaid.nih.gov'; Hensley, Lisa (NIH/NIAID) [E]; Woollen, Neal E LTC USARMY MEDCOM USAMRIID (US); 'anna.bonko@nih.gov'; Geisbert, Tom (tom.geisbert@utmb.edu); Kobinger, Gary (Public Health Agency of Canada)

Cc: Ervin, Elizabeth (CDC/OID/NCEZID) (CTR)

Subject: Ct versus virus isolation

Folks,

(b)(5)

Thanks
Stuart

Feldmann, Heinrich (NIH/NIAID) [E]

(NIH)

From: Ervin, Elizabeth (CDC/OID/NCEZID) (CTR)

Sent: Friday, September 19, 2014 3:00 PM

To: Feldmann, Heinrich (NIH/NIAID) [E]; Rollin, Pierre (CDC/OID/NCEZID); Thorne, Gregory Immel (CDC/CGH/DGHA);

Arlotta, Dawn (CDC/ONDIEH/NCCDPHP); Reed, Christie (CDC/CGH/DPDM)

Subject: RE: (SBU) USAID-OFDA West Africa Ebola Outbreak Update

Hello,

From talking with various parties today, including NIH people on CDC sit-reps (produced MWF), which are then sent out to USG partners, should be an easy addition. Those numbers will be included on Monday's report.

On the Embassy issue, because CDC is not making travel arrangements for NIH staff, no one I spoke to has a good handle on who and when NIH people are arriving and leaving Liberia. Two options for connecting to the Embassy might be:

1. NIH connect directly with Dept. of State. Sharon Jackson (jacksonsp@state.gov) is the DoS liaison to CDC right now and could probably help.
2. Or, we can link NIH deployment coordinators and CDC deployment coordinators so they can regularly communicate arrivals of staff

The first option might be the easiest and most flexible, but if the second option is preferred, please let me know and I will find the appropriate people from CDC to connect with.

Thank you,
Beth

Elizabeth Ervin, MPH

ORISE Fellow

RPCV Philippines '08-'10

Viral Special Pathogens Branch

US Centers for Disease Control and Prevention

404.639.0038 (Office)

wkrc8@cdc.gov